Liquidia Corporation (NASDAQ:LQDA) Stock Has Average Target Price of $98.08

Shares of Liquidia Corporation (NASDAQ:LQDA) have earned an average rating of “Hold” from the twelve analysts that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, six have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $83.69.

LQDA has been the subject of a number of recent research reports. Jefferies Financial Group raised shares of Liquidia to a “strong-buy” rating in a research note on Thursday. Weiss Ratings upgraded Liquidia from a “sell (d-)” rating to a “hold (c)” rating in a research report on Tuesday, September 22nd. Zacks Research lowered Liquidia from a “hold” rating to a “strong sell” rating in a research note on Tuesday, September 22nd. HC Wainwright dropped their target price on Liquidia from $130.00 to $58.00 and set a “buy” rating for the company in a report on Friday. Finally, Wedbush set a $58.00 target price on Liquidia in a research report on Friday.

Insider Activity at Liquidia

In other Liquidia news, Director Katherine Rielly-Gauvin sold 36,789 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $74.99, for a total transaction of $2,758,807.11. Following the transaction, the director owned 44,637 shares in the company, valued at $3,347,328.63. The trade was a 45.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jason Adair sold 73,631 shares of the stock in a transaction on Friday, August 21st. The shares were sold at an average price of $69.09, for a total transaction of $5,087,165.79. Following the completion of the sale, the insider directly owned 174,606 shares in the company, valued at approximately $12,063,528.54. This represents a 29.66% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 597,519 shares of company stock valued at $46,091,764 over the last three months. Corporate insiders own 25.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of LQDA. WINTON GROUP Ltd purchased a new stake in Liquidia in the second quarter worth $335,000. Arizona State Retirement System boosted its stake in shares of Liquidia by 5.4% during the second quarter. Arizona State Retirement System now owns 17,627 shares of the company’s stock valued at $1,405,000 after purchasing an additional 900 shares during the period. Nykredit A S purchased a new stake in shares of Liquidia during the second quarter valued at $177,000. Corient Private Wealth LP bought a new position in shares of Liquidia in the second quarter worth about $758,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Liquidia in the second quarter worth about $1,236,000. Institutional investors own 64.54% of the company’s stock.

Liquidia Stock Up 2.3%

Shares of LQDA opened at $28.64 on Monday. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.31 and a quick ratio of 2.12. The stock has a market capitalization of $2.56 billion, a price-to-earnings ratio of 20.91 and a beta of 0.61. Liquidia has a 1 year low of $21.91 and a 1 year high of $93.61. The business’s 50 day simple moving average is $71.62 and its 200-day simple moving average is $62.02.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). The business had revenue of $171.68 million during the quarter, compared to analysts’ expectations of $168.48 million. Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The company’s revenue for the quarter was up 1842.1% compared to the same quarter last year. During the same period last year, the business posted ($0.49) earnings per share. As a group, equities analysts expect that Liquidia will post 2.57 earnings per share for the current fiscal year.

Key Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia’s legal options are not exhausted: an appeal could potentially overturn or narrow the ruling, giving investors a possible path to recovery if Yutrepia’s market opportunity is preserved. Liquidia Stock Crashed 57% in a Day After a Delaware Court Ruling
• Positive Sentiment: Despite the litigation setback, Jefferies upgraded LQDA to “strong buy,” while HC Wainwright maintained a “buy” rating and set a $58 price target. These calls indicate that some analysts believe the selloff has overstated the long-term damage or that an appeal could succeed.
• Neutral Sentiment: HC Wainwright cut its target from $130 to $58, and Needham reduced its target from $110 to $72, although both retained “buy” ratings. The sharply lower targets reflect materially higher legal and commercialization risk even among bullish analysts.
• Negative Sentiment: BTIG downgraded Liquidia to “neutral,” and Wells Fargo added to the analyst downgrades following the patent ruling. Analysts cited uncertainty over Yutrepia’s PH-ILD indication and the possibility that UTHR’s patent victory could limit Liquidia’s addressable market. Liquidia extends losses as Wells Fargo adds to downgrades
• Negative Sentiment: The court setback triggered a severe selloff, leaving LQDA on track for its worst week on record as investors reassessed Yutrepia’s revenue potential and Liquidia’s competitive position. The stock’s unusually heavy trading volume underscores the market’s heightened uncertainty. LQDA Stock On Track For Worst Week Ever

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).